Cephalon Receives Approvable Letter for Sugar-Free Actiq

The FDA has issued an approvable letter to Cephalon allowing the firm to market a new sugar-free formulation of Actiq.

Actiq (oral transmucosal fentanyl citrate) is indicated only for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.